Fig. 3: PFS of real-world teclistamab in subgroups. | Blood Cancer Journal

Fig. 3: PFS of real-world teclistamab in subgroups.

From: Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Fig. 3: PFS of real-world teclistamab in subgroups.The alt text for this image may have been generated using AI.

A PFS according to prior BCMA exposure. B PFS according to the type of prior BCMA-directed agent. C PFS according to cytogenetic risk. D PFS according to creatinine clearance. E PFS according to penta-drug refractoriness. F PFS according to MajesTEC-1 eligibility.

Back to article page